Press Releases October 6, 2026 08:30 AM

Integra LifeSciences to Host Third Quarter 2026 Financial Results Conference Call on October 21, 2026

Integra LifeSciences Announces Date for Q3 2026 Earnings Release and Conference Call

By Marcus Reed
Share
Twitter Reddit Facebook LinkedIn
IART

Integra LifeSciences Holdings Corporation will announce its third quarter 2026 financial results on October 21, 2026, before market open, followed by a conference call hosted by management. The company operates as a global leader in medical technology, focusing on neurosurgery and tissue reconstruction.

Integra LifeSciences to Host Third Quarter 2026 Financial Results Conference Call on October 21, 2026
IART
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • Announcement of Q3 2026 financial results release date and conference call details.
  • Integra LifeSciences specializes in neurosurgery and tissue reconstruction medical technologies.
  • The company provides a webcast and replay for investor access, promoting transparency.

PRINCETON, N.J., Oct. 06, 2026 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ: IART), a leading global medical technology company, will release third quarter 2026 financial results on Wednesday, October 21, 2026, prior to the market open. In conjunction with the earnings release, Integra’s management team will host a conference call at 8:30 a.m. ET.

A live webcast will be available on the Investors section of the Company’s website at investor.integralife.com. For those planning to participate on the call, register here to receive dial-in details and an individual pin. While not required, joining 10 minutes before the event starts is recommended. A webcast replay of the conference call will be available on the Investors section of the Company’s website following the call.

About Integra LifeSciences

Integra LifeSciences (Nasdaq: IART) is a global medical technology leader dedicated to restoring lives. We are advancing transformational care through impactful innovation in neurosurgery and tissue reconstruction, specialized fields that demand exceptional expertise and precision. Our portfolio of highly differentiated, gold-standard technologies are trusted by healthcare professionals to deliver life-saving care. For our latest news and information, visit www.integralife.com. 

Investor Relations:
Chris Ward
(609) 772-7736
[email protected]   

Media Contact:
Laurene Isip
(609) 208-8121
[email protected] 

Integra LifeSciences Holdings Corporation

Risks

  • Earnings results may fall short of market expectations, impacting stock price.
  • Market conditions in the medical technology sector could affect company performance.
  • Potential uncertainties around product demand in specialized medical fields such as neurosurgery and tissue reconstruction.

More from Press Releases

PacBio and TychoBio Collaborate to Train AI Models for Rare Disease RNA Therapeutics Oct 6, 2026 Repligen Completes Acquisition of BioLife Solutions Oct 6, 2026 Powerus (Nasdaq: PUSA) Receives $82 Million Order for Counter-Unmanned Aerial Systems Oct 6, 2026 NeOnc’s FDA Catalyst Run Could Give NTHI a Serious Jolt Oct 6, 2026 What Are the Best Holiday Gifts People Will Actually Use? Start With Duluth Trading’s Most-Reviewed Bestsellers Oct 6, 2026